Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Relapse of Severe Neurosarcoidosis with Switch from Originator Infliximab to Biosimilar
Neurol 94:991-993, Kidd, D.P.,et al, 2020
Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017
Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Sarcoidosis Presenting as Longitudinally Extensive Myelitis
Neurol 81:e61, Goenka, N. & Venna N., 2013
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Treatment of Refractory Neurosarcoidosis with Infliximab
JNNP 81:241-246, Santos,E., et al, 2010
Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009
Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008
Refractory Neurosarcoidosis Responsive to Infliximab
Pract Neurol 7:112-115, Kobylecki,C. &Shaunak,S., 2007
Refractory Neurosarcoidosis Responding to Infliximab
Neurol 59:1660-1661, Pettersen,J.A.,et al, 2002